XML 240 R194.htm IDEA: XBRL DOCUMENT v3.24.0.1
Legal and arbitral proceedings (Details)
€ in Millions, $ in Millions
 1 Months Ended 12 Months Ended 60 Months Ended 72 Months Ended
Jun. 03, 2022
May 14, 2013
EUR (€)
Sep. 30, 2022
expert
Jul. 31, 2021
manufacturer
Feb. 28, 2021
USD ($)
Oct. 31, 2018
USD ($)
Sep. 30, 2017
EUR (€)
Dec. 31, 2023
EUR (€)
case
person
manufacturer
lawsuit
complaint
plaintiff
action
trial
children
family
claim
patent
Dec. 31, 2021
EUR (€)
trial
Jun. 30, 2021
proceeding
Dec. 31, 2023
EUR (€)
person
manufacturer
lawsuit
complaint
plaintiff
action
trial
children
family
case
claim
Dec. 31, 2023
EUR (€)
person
manufacturer
lawsuit
complaint
plaintiff
action
trial
children
family
case
claim
Dec. 31, 2023
AUD ($)
person
manufacturer
lawsuit
complaint
plaintiff
action
trial
children
family
case
claim
Sep. 30, 2023
claimant
Dec. 31, 2022
EUR (€)
case
claimant
family
Dec. 06, 2022
plaintiff
cancer
Nov. 30, 2022
person
Aug. 20, 2022
ruling
Mar. 31, 2022
patient
Jul. 31, 2020
claim
Dec. 31, 2014
complaint
Nov. 18, 2014
patent
Dec. 31, 1997
EUR (€)
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Provisions for product liability risks, litigation and other               € 1,283.0 € 1,374.0   € 1,283.0 € 1,283.0     € 1,652.0                
Environmental risks               € 493.0 € 650.0   € 493.0 € 493.0     € 526.0                
Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of first instance rulings                             3     7          
Action for which we are defendant | Product liabilities | Minimum                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Litigation amount payable                             € 0.1                
Action for which we are defendant | Product liabilities | Maximum                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Litigation amount payable                             € 0.5                
Sanofi Pasteur Hepatitis B Vaccine product litigation | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of civil individual actions | lawsuit               180     180 180 180                    
Number of ongoing lawsuits | lawsuit               6     6 6 6                    
Taxotere product litigation in the US | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of plaintiffs | plaintiff               6,770     6,770 6,770 6,770                    
Number of bellweather trial held | trial                 2                            
Number of individual cases settled | case               100                              
Taxotere mississippi attorney general litigation in the US | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Maximum penalty amount sought by plaintiffs for each violation | $           $ 10,000                                  
Zantac litigation in the US | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of plaintiffs | plaintiff               26,984     26,984 26,984 26,984                    
Number of cancers associated with dismissed cases | cancer                               5              
Number of plaintiffs who filed notices to appeal | plaintiff                               12,000              
Number of complaints filed | complaint               3,280     3,280 3,280 3,280                    
Zantac litigation in Canada | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of class actions | action                     7                        
Gold Bond Product litigation in the US | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of class actions | action               500                              
Number of ongoing trials | action               0     0 0 0                    
Depakine product litigation in France | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of civil individual actions | claim               79     79 79 79                    
Number of people exposed | person               133     133 133 133                    
Number of lawsuits ruled on merits | lawsuit               30     30 30 30                    
Number of families who filed a civil claim | family                             64                
Number of claimant | claimant                             273                
Number of claimant exposed | claimant                             100                
Number of claimant exposed who withdrawed their claim | claimant                           27                  
Number of indirect victim who withdrawed their claim | claimant                           56                  
Number of experts | expert     2                                        
Number of administrative proceedings | proceeding                   5                          
Depakine product litigation in Switzerland | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of people exposed | person               17     17 17 17                    
Number of families who filed a civil claim | family               11     11 11 11                    
Number of action declared time-barred | person                                 1            
Depakine product litigation in Spain | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of ongoing trials | trial               6     6 6 6                    
Number of people exposed | children               13     13 13 13                    
Number of patients to indemnify | patient                                     4        
Depakine product litigation in Belgium | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of civil individual actions | complaint               2     2 2 2                    
Depakine product litigation in Ireland | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of pre-action protocol cases | case               2     2 2 2                    
Number of civil claims on-going | claim               2     2 2 2                    
Depakine product litigation in Great Britain | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of pre-action protocol cases | case               3     3 3 3                    
Depakine product litigation in Northern Ireland | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of civil claims on-going | claim               1     1 1 1                    
Dengvaxia product litigation in the Philippines | Action for which we are defendant | Product liabilities                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of cases | case                       8                      
Ramipril Canada Patent Litigation | Action for which we are a plaintiff | Patents                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of manufacturers with marketing authorization for generic version of drug | manufacturer               8     8 8 8                    
Praluent (Alirocumab)-related amgen patent litigation in the US | Action for which we are defendant | Patents                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of patent actions initially filed | complaint                                         4    
Number of patents allegedly infringed | patent                                           7  
Jevtana related patent litigation in the US | Action for which we are a plaintiff | Patents                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of patents allegedly infringed | claim                                       12      
Number of patents covering product | patent               4                              
Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Minimum | Patents                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Reduced amount of compensation claimed               € 137.8     € 137.8 € 137.8 $ 223.3                    
Reduced amount of compensation claimed, interest included               218.0     218.0 218.0 360.5                    
Plavix litigation (Commonwealth) in Australia | Action for which we are defendant | Maximum | Patents                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Reduced amount of compensation claimed               172.9     172.9 172.9 280.2                    
Reduced amount of compensation claimed, interest included               € 294.3     € 294.3 € 294.3 $ 487.5                    
Plavix Attorney General Action in Hawaii | Action for which we are defendant                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Total penalty fee incurred by defendants | $         $ 834,012,000                                    
Penalty fee incurred by Sanofi | $         $ 417,006,000                                    
Plavix related litigation in France | Action for which we are defendant                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Penalty fee incurred by Sanofi   € 40.6                                          
Payment of damages claimed by the French CNAM (French Social Security)             € 115.8                                
340B Drug Pricing Program in the United States | Action for which we are defendant                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Number of other manufacturers involved in proceedings | manufacturer       3                                      
Aventis Crop Science retained liabilities | Contingencies arising from certain business divestitures                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Aggregate participation percentage of legacy companies in ACS 76.00%                                            
Infraserv Hoechst retained liabilities | Contingencies arising from certain business divestitures                                              
Disclosure of Legal and Arbitral Proceedings [Line Items]                                              
Fund reserves transferred                                             € 57.0
Maximum amount to be reimbursed for current and future environmental expense                                             € 143.0